Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

Autor: Dennis J. Slamon, Thomas Bachelot, Erik Jakobsen, Rashmi Krishna Murthy, Alicia Okines, David Cameron, Lisa A. Carey, Giuseppe Curigliano, Ian E. Krop, Karen A. Gelmon, Volkmar Müller, Nan Lin, Virginia F. Borges, Eric P. Winer, Gabriel N. Hortobagyi, Philippe L. Bedard, Richard Greil, Sara A. Hurvitz, François Duhoux, Luke Walker, Sofia Braga, Elisavet Paplomata, M Corinna Palanca-Wessels, Sherene Loi, Vandana G. Abramson, Mafalda Oliveira, Carey K. Anders, Wentao Feng, Mark D. Pegram, Shlomit S. Shachar, Sibylle Loibl, Erika Hamilton

Publikováno v: K Murthy, R, Loi, S, Okines, A, Paplomata, E, Hamilton, E, A. Hurvitz, S, U. Lin, N, Borges, V, Abramson, V, Anders, C, L. Bedard, P, Oliveira, M, Jakobsen, E, Bachelot, T, S. Shachar, S, Müller, V, Braga, S, P. Duhoux, F, Greil, R, Cameron, D, A. Carey, L, Curigliano, G, Gelmon, K, Hortobagyi, G, Krop, I, Loibl, S, Pegram, M, Slamon, D, Palanca-Wessels, M C, Walker, L, Feng, W & P. Winer, E 2020, ' Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer ', New England Journal of Medicine, vol. 382, no. 7, pp. 597-609 . https://doi.org/10.1056/NEJMoa1914609
Murthy, R K, Loi, S, Okines, A, Paplomata, E, Hamilton, E, Hurvitz, S A, Lin, N U, Borges, V, Abramson, V, Anders, C, Bedard, P L, Oliveira, M, Jakobsen, E, Bachelot, T, Shachar, S S, Muller, V, Braga, S, Duhoux, F P, Greil, R, Cameron, D, Carey, L A, Curigliano, G, Gelmon, K, Hortobagyi, G, Krop, I, Loibl, S, Pegram, M, Slamon, D, Palanca-Wessels, M C, Walker, L, Feng, W & Winer, E P 2020, ' Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer ', New England Journal of Medicine, vol. 382, no. 7, pp. 597-609 . https://doi.org/10.1056/NEJMoa1914609
The New England journal of medicine, Vol. 382, no. 7, p. 597-609 (2020)

BACKGROUND: Patients with human epidermal growth factor receptor 2 (HER2)–positive metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted agents have limited treatment options. Tucatinib is an investigationa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5309a1bc026281d5d475def4ba6ca36
https://www.pure.ed.ac.uk/ws/files/125147047/NEJMoa1914609.pdf

Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study

Autor: Zhiyuan Hu, Erin L. Kirk, Charles M. Perou, Emma H. Allott, Michelle Mathews, Yan Li, Chiu Kit Tse, Joseph Geradts, Andrew F. Olshan, Melissa A. Troester, Whitney R. Robinson, Xuezheng Sun, H. Shelton Earp, Olufunmilayo I. Olopade, Lisa A. Carey, Stephanie M. Cohen, Leigh B. Thorne, Katherine E. Reeder-Hayes, Katherine A. Hoadley

Publikováno v: Troester, M A, Sun, X, Allott, E H, Geradts, J, Cohen, S M, Tse, C-K, Kirk, E L, Thorne, L B, Mathews, M, Li, Y, Hu, Z, Robinson, W R, Hoadley, K A, Olopade, O I, Reeder-Hayes, K E, Earp, H S, Olshan, A F, Carey, L A & Perou, C M 2018, ' Racial Differences in PAM50 Subtypes in the Carolina Breast Cancer Study ', Journal of the National Cancer Institute, vol. 110, no. 2, pp. 176-182 . https://doi.org/10.1093/jnci/djx135

Background: African American breast cancer patients have lower frequency of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2 (HER2)-negative disease and higher subtype-specific mortality. Racial differences in molecular subtyp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::245662e665d2a8e22d51fb573efea0dc
https://europepmc.org/articles/PMC6059138/

TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial

Autor: Emmanuel Blot, Tanja Cufer, Hervé Bonnefoi, Jonas Bergh, Louis Mauriac, Martine Piccart, Sylvie André, Elisabet Lidbrink, P. Rouanet, Khalil Zaman, Alain Lortholary, Etienne Brain, Saskia Litière, Jacek Jassem, Thierry Petit, David Cameron, Jan Bogaerts, Richard Iggo, Pierre Fumoleau, Lissandra Dal Lago, Véronique Becette

Publikováno v: Lancet Oncology, vol. 12, no. 6, pp. 527-539

TP53 has a crucial role in the DNA damage response. We therefore tested the hypothesis that taxanes confer a greater advantage than do anthracyclines on breast cancers with mutated TP53 than in those with wild-type TP53.In an open-label, phase 3 stud

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e902924f2afe2ec63bce2eed8005cdf9
https://doi.org/10.1016/s1470-2045(11)70094-8

Dynamic prediction in breast cancer: proving feasibility in clinical practice using the TEAM trial

Autor: M. Klinten Grand, L Dirix, J.W.R. Nortier, Caroline Seynaeve, Hein Putter, C.J.H. van de Velde, D.B.Y. Fontein, E. Meershoek-Klein Kranenbarg

Publikováno v: Annals of Oncology, 26(6), 1254-1262. Elsevier Ltd.
Fontein, D B Y, Klinten Grand, M, Nortier, J W R, Seynaeve, C, Meershoek-Klein Kranenbarg, E, Dirix, L Y, van de Velde, C J H & Putter, H 2015, ' Dynamic prediction in breast cancer : proving feasibility in clinical practice using the TEAM trial ', Annals of Oncology, vol. 26, no. 6, pp. 1254-62 . https://doi.org/10.1093/annonc/mdv146
Annals of Oncology, 26(6), 1254-1262

BACKGROUND: Predictive models are an integral part of current clinical practice and help determine optimal treatment strategies for individual patients. A drawback is that covariates are assumed to have constant effects on overall survival (OS), when

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93a5faab0308c33326f975a94e16c89e
https://pure.eur.nl/en/publications/8f09789c-5f20-4198-ac2f-4230a9a26317

A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer

Autor: Bamias, A., Karina, M., Papakostas, P., Kostopoulos, I., Bobos, M., Vourli, G., Samantas, E., Christodoulou, Ch, Pentheroudakis, G., Pectasides, D., Dimopoulos, M. A., Fountzilas, G.

The optimal adjuvant treatment for gastric cancer remains controversial. We compared the efficacy of a docetaxel and platinum adjuvant chemotherapy regimen, in patients with high-risk gastric cancer, with that of the same chemotherapy plus radiation

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10561::b8ecd160c0f1fc7e14577013d8fe469c
http://olympias.lib.uoi.gr/jspui/handle/123456789/24247